CureVac AG

https://www.curevac.com

Founded in 2000 as a spin-off from the University of T?bingen in Germany, CureVac is a technology leader in the development of drugs that are based on Messenger RNA (mRNA). The company has more than 15 years of expertise in handling and optimizing this versatile molecule for medical purposes and has the most advanced product pipeline and IP portfolio in the industry. The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. Since its inception, CureVac has received approximately $330 million (€300 million) in equity investments. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, the Bill & Melinda Gates Foundation and IAVI. In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac will start the construction of an industrial scale production facility with a capacity of 30 million doses per year. *

	Start	2015-11-02 renamed (reorg)
	End	2022-09-26 reorganised
	Group	CureVac (Group)
	Today	CureVac SE
	Predecessor	CureVac GmbH
	Successor	CureVac SE
	Industry	RNAi technology
	Industry 2	RNActive® vaccination technology
	Person	Hoerr, Ingmar (CureVac 201806– Chairman of Supervisory Board before 2000–201806 CEO + Co-Founder)

	Region	Tübingen
	Country	Germany
	Street	15 Friedrich-Miescher-Str.
	City	72076 Tübingen
	Tel	+49-7071-92053-0
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2017-10-26)

		* Document for »About Section«:

		Record changed: 2023-12-30